초대 간세포 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Primary Hepatocytes Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

US $ 4,995 ￦ 6,843,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 9,994,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,638,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 이번에 세계의 초대 간세포 시장에 관한 종합 보고서를 발표했습니다. 시장 성장 촉진요인·동향·기회·촉진요인·과제등의 중요한 시장 역학을 철저하게 평가하고, 시장 구조에 관한 상세 인사이트를 제공하고 있습니다. 이 조사 리포트는 세계의 초대 간세포 시장의 2025-2032년 예측 성장 궤도를 설명하는 독점 데이터와 통계를 게재하고 있습니다.

주요 인사이트

• 초대 간세포 시장 규모(2025년) : 2억 7,290만 달러
• 예측 시장가치(2032년) : 4억 2,820만 달러
• 세계 시장 성장률(CAGR 2025-2032년) : 6.6%

초대 간세포 시장 - 리포트 범위 :

간세포는 제약연구, 독성시험, 약물개발에 필수적인 툴로 작용하는 특수 간세포입니다. 이 세포들은 신약개발, 간독성 시험, 간질환의 in-vitro 모델 등에 널리 사용되고 있습니다. 1차 간세포 시장은 연구기관, 제약회사, 의약품 개발업무수탁기관(CRO)에 대응하고 있으며, 인간 1차 간세포, 쥐 간세포, 불멸화 간세포 등 다양한 간세포 제품을 공급하고 있습니다. 시장 성장의 원동력은 맞춤형 의료에 대한 수요 증가, 세포배양 기술의 발전, 보다 정확한 약물 검사 모델에 대한 니즈 증가입니다.

시장 성장 촉진요인:

세계 간세포 시장은 맞춤형 의료에 대한 수요 증가, 신약 개발 및 독성 테스트에서 신뢰할 수 있는 체외 시험 모델에 대한 수요 증가 등 몇 가지 주요 요인에 의해 주도되고 있습니다. 간세포는 간 기능 평가, 화합물 대사, 간 질환 연구에 매우 중요하며, 의약품 연구개발에 광범위하게 사용되고 있습니다. 첨단 간세포 분리 기술 및 개선된 세포배양 시스템 개발과 같은 기술 발전은 간세포의 성능과 유용성을 향상시켜 시장 확대를 더욱 촉진하고 있습니다. 또한 비동물 실험법에 대한 관심 증가와 간 관련 질환 증가는 의학 연구 분야에서 1차 간세포의 채택 확대에 기여하고 있습니다.

시장 성장 억제요인:

유망한 성장 전망에도 불구하고 1차 간세포 시장은 1차 간세포 분리 배양 시스템의 높은 비용에 대한 문제에 직면해 있습니다. 이러한 기술에는 전문 장비와 숙련된 인력이 필요하며, 소규모 연구소나 예산이 한정된 기관에서는 1차 간세포의 활용이 제한적일 수 있습니다. 또한 인간 간조직공급이 제한되어 있고, 간세포 조달과 관련된 윤리적 문제가 시장 성장에 큰 장벽이 될 수 있습니다. 규제 장벽과 제약 연구에서의 엄격한 가이드라인 준수에 대한 필요성은 신규 진출기업에게 시장 진입을 더욱 복잡하게 만들고 있습니다.

시장 기회:

세포배양 기술의 혁신, 간 질환 연구의 발전, 대체 약물 시험 모델에 대한 수요 증가로 인해 간세포 시장은 큰 성장 기회를 제공합니다. 간경변증, 간염 등 만성 간질환 증가와 맞춤형 의료 접근법의 채택 확대로 시장 기업은 간세포를 기반으로 보다 효과적인 솔루션을 개발할 수 있는 새로운 수단을 확보할 수 있습니다. 제약사, CRO, 연구기관 간의 전략적 파트너십은 연구개발에 대한 투자와 함께 새로운 기회를 활용하고 시장에서의 리더십을 유지하기 위해 매우 중요합니다.

이 보고서에서 다룬 주요 질문

• 전 세계 간세포 시장의 성장을 가속하는 주요 요인은 무엇인가?
• 다양한 연구 환경에서 어떤 간세포 유형과 용도가 1차 간세포 수요를 주도하고 있는가?
• 기술의 발전은 어떻게 간세포 시장 경쟁 구도를 바꾸고 있는가?
• 초기 간세포 시장에 기여하고 있는 주요 기업은 어디이며, 시장 관련성을 유지하기 위해 어떤 전략을 채택하고 있는가?
• 세계 1차 간세포 시장의 새로운 동향과 전망은?

목차

제1장 개요

제2장 시장 개요

• 시장의 범위와 정의
• 시장 역학
  • 촉진요인
  • 억제요인
  • 기회
  • 과제
  • 주요 동향
• 거시경제 요인
  • 세계의 부문별 전망
  • 세계의 GDP 성장 전망
  • 세계의 헬스케어 지출 전망
• COVID-19의 영향 분석
• 예측 요인 - 관련성과 영향

제3장 부가가치 인사이트

• 규제 상황
• 제품 채택 분석
• 밸류체인 분석
• 주요 거래와 합병
• PESTLE 분석
• Porter's Five Forces 분석

제4장 세계의 초대 간세포 시장 전망 :

• 주요 하이라이트
  • 시장 규모와 전년대비 성장률
  • 절대적 매출 기회
• 시장 규모 분석과 예측
  • 과거 시장 규모 분석, 2019-2024년
  • 현재 시장 규모 분석과 예측, 2025-2032년
• 세계의 초대 간세포 시장 전망 : 제품
  • 서론/주요 조사 결과
  • 과거 시장 규모 분석, 제품별, 2019-2024년
  • 현재 시장 규모 분석과 예측, 제품별, 2025-2032년
    • 동결 보존된 부유 간세포
    • 신선 현탁액 간세포
    • 3D(스페로이드) 간세포
    • 증식 간세포(배양 가능)
    • 미해석 간세포
  • 시장의 매력 분석 : 제품
• 세계의 초대 간세포 시장 전망 : 종
  • 서론/주요 조사 결과
  • 2019-2024년에서 유형별 시장 규모의 과거 분석
  • 현재 시장 규모 분석과 예측, 유형별, 2025-2032년
    • 인간
    • 쥐
    • 마우스
    • 개
    • 원숭이
    • 말
    • 기타
  • 시장의 매력 분석 : 종
• 세계의 초대 간세포 시장 전망 : 애플리케이션/어세이
  • 서론/주요 조사 결과
  • 과거 시장 규모 분석, 애플리케이션/어세이별, 2019-2024년
  • 현재 시장 규모 분석과 예측, 애플리케이션/어세이별, 2025-2032년
    • 세포 생존률 어세이
    • 시토크롬 효소 활성
    • 고농도 세포 독성
    • 트랜스포터 저해 어세이
    • 체외 고유 클리어런스
    • 인지질 어세이
    • 기타
  • 시장의 매력 분석 : 애플리케이션/어세이
• 세계의 초대 간세포 시장 전망 : 최종사용자
  • 서론/주요 조사 결과
  • 과거 시장 규모 분석, 최종사용자별, 2019-2024년
  • 현재 시장 규모 분석과 예측, 최종사용자별, 2025-2032년
    • 바이오의약품 기업
    • 학술 조사기관
    • 계약 조사기관
  • 시장의 매력 분석 : 최종사용자

제5장 세계의 초대 간세포 시장 전망 : 지역

• 주요 하이라이트
• 2019-2024년 지역별 시장 규모의 역사 목표 분석
• 현재 시장 규모 분석과 예측, 지역별, 2025-2032년
  • 북미
  • 유럽
  • 동아시아
  • 남아시아와 오세아니아
  • 라틴아메리카
  • 중동 및 아프리카
• 시장의 매력 분석 : 지역

제6장 북미의 초대 간세포 시장 전망 :

제7장 유럽의 초대 간세포 시장 전망 :

제8장 동아시아의 초대 간세포 시장 전망 :

제9장 남아시아 및 오세아니아의 초대 간세포 시장 전망 :

제10장 라틴아메리카의 초대 간세포 시장 전망 :

제11장 중동 및 아프리카의 초대 간세포 시장 전망 :

제12장 경쟁 구도

• 시장 점유율 분석, 2025년
• 시장 구조
  • 시장별 경쟁 격화 맵
  • 경쟁 대시보드
• 기업 개요(상세-개요, 재무, 전략, 최근 동향)
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Lonza
  • Takara Bio Inc.
  • American Type Culture Collection(ATCC)
  • Corning Inc.
  • Cell Biologics, Inc.
  • Creative Bioarray
  • Axol Bioscience Ltd.
  • HiMedia Laboratories
  • NEXEL Co., Ltd.
  • AnaBios
  • Cytes Biotechnologies SL
  • ZenBio, Inc.(BioIVT)
  • iXCells Biotechnologies
  • ScienCell Research Laboratories, Inc.
  • Kerafast
  • Kosheeka
  • XenoTech
  • LifeNet Health LifeSciences
  • Cell Guidance Systems LLC
  • Applied Biological Materials Inc.(abm)
  • Discovery Life Sciences
  • Innoprot
  • Novabiosis

제13장 부록

• 조사 방법
• 조사의 전제
• 두자어와 약어

KSA

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the worldwide market for primary hepatocytes. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global primary hepatocytes market from 2025 to 2032.

Key Insights:

• Primary Hepatocytes Market Size (2025E): US$ 272.9 Mn
• Projected Market Value (2032F): US$ 428.2 Mn
• Global Market Growth Rate (CAGR 2025 to 2032): 6.6%

Primary Hepatocytes Market - Report Scope:

Primary hepatocytes are specialized liver cells that serve as essential tools for pharmaceutical research, toxicity testing, and drug development. These cells are widely used in drug discovery, hepatotoxicity testing, and in-vitro models for liver diseases. The primary hepatocytes market caters to research institutions, pharmaceutical companies, and contract research organizations (CROs), offering a variety of hepatocyte products, including human primary hepatocytes, rat hepatocytes, and immortalized hepatocytes. Market growth is driven by increasing demand for personalized medicine, advancements in cell culture technology, and the rising need for more accurate drug testing models.

Market Growth Drivers:

The global primary hepatocytes market is propelled by several key factors, including the growing demand for personalized medicine and the rising need for reliable in-vitro testing models in drug discovery and toxicity testing. Hepatocytes are crucial in assessing liver function, metabolizing compounds, and studying liver diseases, leading to their widespread adoption in pharmaceutical R&D. Technological advancements, such as the development of advanced hepatocyte isolation techniques and improved cell culture systems, have enhanced the performance and utility of primary hepatocytes, further boosting market expansion. Moreover, the growing focus on non-animal testing methods and the increasing number of liver-related diseases contribute to the rising adoption of primary hepatocytes in medical research.

Market Restraints:

Despite promising growth prospects, the primary hepatocytes market faces challenges related to the high cost of primary hepatocyte isolation and culture systems. These techniques require specialized equipment and skilled personnel, which can limit the accessibility of primary hepatocytes to smaller laboratories or institutions with limited budgets. Additionally, the limited supply of human liver tissue and ethical concerns associated with sourcing hepatocytes can pose significant barriers to market growth. Regulatory hurdles and the need for compliance with stringent guidelines in pharmaceutical research further complicate market entry for new players.

Market Opportunities:

The primary hepatocytes market presents significant growth opportunities driven by innovations in cell culture technology, advancements in liver disease research, and increasing demand for alternative drug testing models. The rise in chronic liver diseases such as cirrhosis and hepatitis, along with the growing adoption of personalized medicine approaches, provides new avenues for market players to develop more effective hepatocyte-based solutions. Strategic partnerships between pharmaceutical companies, CROs, and research institutions, alongside investments in R&D, are crucial to capitalize on emerging opportunities and sustain market leadership.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the primary hepatocytes market globally?
• Which hepatocyte types and applications are driving the demand for primary hepatocytes across different research settings?
• How are technological advancements reshaping the competitive landscape of the primary hepatocytes market?
• Who are the key players contributing to the primary hepatocytes market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global primary hepatocytes market?

Competitive Intelligence and Business Strategy:

Leading players in the global primary hepatocytes market, including Thermo Fisher Scientific, Lonza Group, and Merck KGaA, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced hepatocyte culture systems, liver-on-a-chip models, and improved hepatocyte isolation techniques, catering to diverse research needs. Collaborations with pharmaceutical companies, biotechnology firms, and academic research institutions facilitate market access and promote the development of more effective hepatocyte-based solutions. Moreover, emphasis on clinical research, drug development, and regulatory compliance fosters market growth and enhances product offerings in the evolving hepatocyte market.

Key Companies Profiled:

• Thermo Fisher Scientific
• Lonza Group
• Merck KGaA
• Sigma-Aldrich (now part of Merck)
• BioIVT
• CellzDirect (a part of Thermo Fisher)
• In Vitro Technologies
• Primorigen Biosciences
• PharmaCyte Biotech
• Wuxi AppTec

Global Primary Hepatocytes Market Segmentation

By Product

• Cryopreserved Suspension Hepatocytes
• Fresh Suspension Hepatocytes
• 3D (Spheroid) Hepatocytes
• Expanded Hepatocytes (Plateable)
• Non-characterized Hepatocytes

By Species

• Human
• Rat
• Mouse
• Dog
• Monkey
• Horse

By Application/Assay

• Cell Viability Assay
• Cytochrome Enzyme Activity
• High Content Cytotoxicity
• Transporter Inhibition Assay
• In Vitro Intrinsic Clearance
• Phospholipids Assay

By End User

• Biopharmaceutical companies
• Academic and Research institutes
• Contract Research Organizations

By Region

• North America
• Europe
• East Asia
• South Asia & Oceania
• Latin America
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Primary Hepatocytes Market Snapshot, 2025-2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Regulatory Landscape
• 3.2. Product Adoption Analysis
• 3.3. Value Chain Analysis
• 3.4. Key Deals and Mergers
• 3.5. PESTLE Analysis
• 3.6. Porter's Five Force Analysis

4. Global Primary Hepatocytes Market Outlook:

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
• 4.3. Global Primary Hepatocytes Market Outlook: Product
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 4.3.3.1. Cryopreserved Suspension Hepatocytes
    • 4.3.3.2. Fresh Suspension Hepatocytes
    • 4.3.3.3. 3D (Spheroid) Hepatocytes
    • 4.3.3.4. Expanded Hepatocytes (Plateable)
    • 4.3.3.5. Non-characterized Hepatocytes
  • 4.3.4. Market Attractiveness Analysis: Product
• 4.4. Global Primary Hepatocytes Market Outlook: Species
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Mn) Analysis, By Species, 2019-2024
  • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
    • 4.4.3.1. Human
    • 4.4.3.2. Rat
    • 4.4.3.3. Mouse
    • 4.4.3.4. Dog
    • 4.4.3.5. Monkey
    • 4.4.3.6. Horse
    • 4.4.3.7. Others
  • 4.4.4. Market Attractiveness Analysis: Species
• 4.5. Global Primary Hepatocytes Market Outlook: Application/Assay
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn) Analysis, By Application/Assay, 2019-2024
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
    • 4.5.3.1. Cell Viability Assay
    • 4.5.3.2. Cytochrome Enzyme Activity
    • 4.5.3.3. High Content Cytotoxicity
    • 4.5.3.4. Transporter Inhibition Assay
    • 4.5.3.5. In Vitro Intrinsic Clearance
    • 4.5.3.6. Phospholipids Assay
    • 4.5.3.7. Others
  • 4.5.4. Market Attractiveness Analysis: Application/Assay
• 4.6. Global Primary Hepatocytes Market Outlook: End User
  • 4.6.1. Introduction / Key Findings
  • 4.6.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
  • 4.6.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 4.6.3.1. Biopharmaceutical companies
    • 4.6.3.2. Academic and Research institutes
    • 4.6.3.3. Contract Research Organizations
  • 4.6.4. Market Attractiveness Analysis: End User

5. Global Primary Hepatocytes Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Primary Hepatocytes Market Outlook:

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Product
  • 6.2.3. By Species
  • 6.2.4. By Application/Assay
  • 6.2.5. By End User
• 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 6.4.1. Cryopreserved Suspension Hepatocytes
  • 6.4.2. Fresh Suspension Hepatocytes
  • 6.4.3. 3D (Spheroid) Hepatocytes
  • 6.4.4. Expanded Hepatocytes (Plateable)
  • 6.4.5. Non-characterized Hepatocytes
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
  • 6.5.1. Human
  • 6.5.2. Rat
  • 6.5.3. Mouse
  • 6.5.4. Dog
  • 6.5.5. Monkey
  • 6.5.6. Horse
  • 6.5.7. Others
• 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
  • 6.6.1. Cell Viability Assay
  • 6.6.2. Cytochrome Enzyme Activity
  • 6.6.3. High Content Cytotoxicity
  • 6.6.4. Transporter Inhibition Assay
  • 6.6.5. In Vitro Intrinsic Clearance
  • 6.6.6. Phospholipids Assay
  • 6.6.7. Others
• 6.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 6.7.1. Biopharmaceutical companies
  • 6.7.2. Academic and Research institutes
  • 6.7.3. Contract Research Organizations
• 6.8. Market Attractiveness Analysis

7. Europe Primary Hepatocytes Market Outlook:

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Product
  • 7.2.3. By Species
  • 7.2.4. By Application/Assay
  • 7.2.5. By End User
• 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 7.4.1. Cryopreserved Suspension Hepatocytes
  • 7.4.2. Fresh Suspension Hepatocytes
  • 7.4.3. 3D (Spheroid) Hepatocytes
  • 7.4.4. Expanded Hepatocytes (Plateable)
  • 7.4.5. Non-characterized Hepatocytes
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
  • 7.5.1. Human
  • 7.5.2. Rat
  • 7.5.3. Mouse
  • 7.5.4. Dog
  • 7.5.5. Monkey
  • 7.5.6. Horse
  • 7.5.7. Others
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
  • 7.6.1. Cell Viability Assay
  • 7.6.2. Cytochrome Enzyme Activity
  • 7.6.3. High Content Cytotoxicity
  • 7.6.4. Transporter Inhibition Assay
  • 7.6.5. In Vitro Intrinsic Clearance
  • 7.6.6. Phospholipids Assay
  • 7.6.7. Others
• 7.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 7.7.1. Biopharmaceutical companies
  • 7.7.2. Academic and Research institutes
  • 7.7.3. Contract Research Organizations
• 7.8. Market Attractiveness Analysis

8. East Asia Primary Hepatocytes Market Outlook:

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Product
  • 8.2.3. By Species
  • 8.2.4. By Application/Assay
  • 8.2.5. By End User
• 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 8.4.1. Cryopreserved Suspension Hepatocytes
  • 8.4.2. Fresh Suspension Hepatocytes
  • 8.4.3. 3D (Spheroid) Hepatocytes
  • 8.4.4. Expanded Hepatocytes (Plateable)
  • 8.4.5. Non-characterized Hepatocytes
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
  • 8.5.1. Human
  • 8.5.2. Rat
  • 8.5.3. Mouse
  • 8.5.4. Dog
  • 8.5.5. Monkey
  • 8.5.6. Horse
  • 8.5.7. Others
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
  • 8.6.1. Cell Viability Assay
  • 8.6.2. Cytochrome Enzyme Activity
  • 8.6.3. High Content Cytotoxicity
  • 8.6.4. Transporter Inhibition Assay
  • 8.6.5. In Vitro Intrinsic Clearance
  • 8.6.6. Phospholipids Assay
  • 8.6.7. Others
• 8.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 8.7.1. Biopharmaceutical companies
  • 8.7.2. Academic and Research institutes
  • 8.7.3. Contract Research Organizations
• 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Primary Hepatocytes Market Outlook:

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Product
  • 9.2.3. By Species
  • 9.2.4. By Application/Assay
  • 9.2.5. By End User
• 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 9.4.1. Cryopreserved Suspension Hepatocytes
  • 9.4.2. Fresh Suspension Hepatocytes
  • 9.4.3. 3D (Spheroid) Hepatocytes
  • 9.4.4. Expanded Hepatocytes (Plateable)
  • 9.4.5. Non-characterized Hepatocytes
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
  • 9.5.1. Human
  • 9.5.2. Rat
  • 9.5.3. Mouse
  • 9.5.4. Dog
  • 9.5.5. Monkey
  • 9.5.6. Horse
  • 9.5.7. Others
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
  • 9.6.1. Cell Viability Assay
  • 9.6.2. Cytochrome Enzyme Activity
  • 9.6.3. High Content Cytotoxicity
  • 9.6.4. Transporter Inhibition Assay
  • 9.6.5. In Vitro Intrinsic Clearance
  • 9.6.6. Phospholipids Assay
  • 9.6.7. Others
• 9.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 9.7.1. Biopharmaceutical companies
  • 9.7.2. Academic and Research institutes
  • 9.7.3. Contract Research Organizations
• 9.8. Market Attractiveness Analysis

10. Latin America Primary Hepatocytes Market Outlook:

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Product
  • 10.2.3. By Species
  • 10.2.4. By Application/Assay
  • 10.2.5. By End User
• 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 10.4.1. Cryopreserved Suspension Hepatocytes
  • 10.4.2. Fresh Suspension Hepatocytes
  • 10.4.3. 3D (Spheroid) Hepatocytes
  • 10.4.4. Expanded Hepatocytes (Plateable)
  • 10.4.5. Non-characterized Hepatocytes
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
  • 10.5.1. Human
  • 10.5.2. Rat
  • 10.5.3. Mouse
  • 10.5.4. Dog
  • 10.5.5. Monkey
  • 10.5.6. Horse
  • 10.5.7. Others
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
  • 10.6.1. Cell Viability Assay
  • 10.6.2. Cytochrome Enzyme Activity
  • 10.6.3. High Content Cytotoxicity
  • 10.6.4. Transporter Inhibition Assay
  • 10.6.5. In Vitro Intrinsic Clearance
  • 10.6.6. Phospholipids Assay
  • 10.6.7. Others
• 10.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 10.7.1. Biopharmaceutical companies
  • 10.7.2. Academic and Research institutes
  • 10.7.3. Contract Research Organizations
• 10.8. Market Attractiveness Analysis

11. Middle East & Africa Primary Hepatocytes Market Outlook:

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Product
  • 11.2.3. By Species
  • 11.2.4. By Application/Assay
  • 11.2.5. By End User
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 11.4.1. Cryopreserved Suspension Hepatocytes
  • 11.4.2. Fresh Suspension Hepatocytes
  • 11.4.3. 3D (Spheroid) Hepatocytes
  • 11.4.4. Expanded Hepatocytes (Plateable)
  • 11.4.5. Non-characterized Hepatocytes
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
  • 11.5.1. Human
  • 11.5.2. Rat
  • 11.5.3. Mouse
  • 11.5.4. Dog
  • 11.5.5. Monkey
  • 11.5.6. Horse
  • 11.5.7. Others
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
  • 11.6.1. Cell Viability Assay
  • 11.6.2. Cytochrome Enzyme Activity
  • 11.6.3. High Content Cytotoxicity
  • 11.6.4. Transporter Inhibition Assay
  • 11.6.5. In Vitro Intrinsic Clearance
  • 11.6.6. Phospholipids Assay
  • 11.6.7. Others
• 11.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 11.7.1. Biopharmaceutical companies
  • 11.7.2. Academic and Research institutes
  • 11.7.3. Contract Research Organizations
• 11.8. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Thermo Fisher Scientific Inc.
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Merck KGaA
  • 12.3.3. Lonza
  • 12.3.4. Takara Bio Inc.
  • 12.3.5. American Type Culture Collection (ATCC)
  • 12.3.6. Corning Inc.
  • 12.3.7. Cell Biologics, Inc.
  • 12.3.8. Creative Bioarray
  • 12.3.9. Axol Bioscience Ltd.
  • 12.3.10. HiMedia Laboratories
  • 12.3.11. NEXEL Co., Ltd.
  • 12.3.12. AnaBios
  • 12.3.13. Cytes Biotechnologies S.L.
  • 12.3.14. ZenBio, Inc. (BioIVT)
  • 12.3.15. iXCells Biotechnologies
  • 12.3.16. ScienCell Research Laboratories, Inc.
  • 12.3.17. Kerafast
  • 12.3.18. Kosheeka
  • 12.3.19. XenoTech
  • 12.3.20. LifeNet Health LifeSciences
  • 12.3.21. Cell Guidance Systems LLC
  • 12.3.22. Applied Biological Materials Inc. (abm)
  • 12.3.23. Discovery Life Sciences
  • 12.3.24. Innoprot
  • 12.3.25. Novabiosis

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations

관련자료